Key result
Spinal cord stimulation provides symptomatic benefits, improved quality of life, and functional improvement for refractory angina pectoris, with cost-effectiveness break-even at 15-16 months.
Why the study?
Does spinal cord stimulation improve symptoms and quality of life in patients with refractory angina pectoris?
Does spinal cord stimulation improve symptoms and quality of life in patients with refractory angina pectoris?
Spinal cord stimulation is an effective and cost-effective treatment for refractory angina pectoris, providing significant symptomatic relief and improved quality of life.
Answers are grounded in this paper and cite their sources.
May support SCS for refractory angina symptoms; leaves open need for RCTs to confirm efficacy.
Patients who continue to suffer from severe and disabling angina pectoris, despite optimum treatment in terms of conventional pharmacological therapy and/or revascularization procedures, have been termed as having refractory angina pectoris. The future group of patients with refractory angina pectoris will be different from today's patients and represent a 'moving target' as risk factors, efficacy of treatment and indications continue to change. Spinal cord stimulation (SCS) is today considered as first-line treatment of refractory angina pectoris, by the European Society of Cardiology, with an anti-ischemic effect. There is strong evidence for SCS giving symptomatic benefits (decrease in anginal attacks), improved quality of life and improvement of functional status. In addition, SCS seems to be cost effective with a 'break-even' after approximately 15-16 months.
No takes yet. Share an insight, caveat, or question.
Börjesson et al. (2011) conducted a review in Refractory angina pectoris. Spinal cord stimulation (SCS) was evaluated on Symptomatic benefits, quality of life, and functional status. Spinal cord stimulation provides symptomatic benefits, improved quality of life, and functional improvement for refractory angina pectoris, with cost-effectiveness break-even at 15-16 months.
Synapse has enriched 10 related papers. Consider them for comparative context: